Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

(2015) Marion Zillhardt et al.   NEOPLASIA

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

(2013) Richard Schwab et al.   LUNG CANCER

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

(2012) Farbod Shojaei et al.   CANCER LETTERS

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

(2012) Giorgio Scagliotti et al.   EUROPEAN JOURNAL OF CANCER

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma

(2012) Sacha I. Rothschild et al.   Journal of Thoracic Oncology

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

(2012) Hiroyuki Yasuda et al.   Journal of Thoracic Oncology

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

(2012) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma

(2012) S I Rothschild et al.   ONCOGENE

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

(2011) Junko Tanizaki et al.   Journal of Thoracic Oncology

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

(2010) Giuseppe Bronte et al.   CANCER TREATMENT REVIEWS

Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer

(2010) B. Sen et al.   CLINICAL CANCER RESEARCH

ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?

(2010) Ken Garber   JNCI-Journal of the National Cancer Institute

The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells

(2010) Phillip R. Purnell et al.   Journal of Thoracic Oncology

The stem cell gene “inhibitor of differentiation 1” (ID1) is frequently expressed in non-small cell lung cancer

(2010) Sacha I. Rothschild et al.   LUNG CANCER

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

(2010) Filip Janku et al.   Nature Reviews Clinical Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

(2009) Takeshi Yoshida et al.   CANCER SCIENCE

Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer

(2008) O. Gautschi et al.   CANCER RESEARCH

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH